Christodoulidis Grigorios, Tsagkidou Kyriaki, Bartzi Dimitra, Prisacariu Ioana Alexandra, Agko Eirini Sara
Department of General Surgery, University Hospital of Larissa, Larissa 41110, Greece.
Department of Gastroenterology, University Hospital of Larisa, Larisa 41100, Greece.
World J Gastrointest Endosc. 2025 May 16;17(5):105580. doi: 10.4253/wjge.v17.i5.105580.
Non-variceal upper gastrointestinal bleeding (GIB) remains a significant clinical challenge with a 30-day mortality of up to 11%. Peptic ulcers are the most common cause, followed by other conditions like Mallory-Weiss syndrome, Dieulafoy's lesions, and gastric neoplasms. Treatment strategies include acid-suppressive therapy, endoscopic interventions, and surgical or radiological procedures. Endoscopic techniques such as over-the-scope clips, coagulation graspers, and endoscopic ultrasound-guided treatments have significantly improved outcomes, reducing rebleeding rates and the need for surgery. Injectable therapies, mechanical hemostasis clips, and thermal modalities (, electrocoagulation, argon plasma coagulation) remain standard approaches for active bleeding. Newer hemostatic powders, such as TC-325, offer promising non-contact treatments, particularly in cases of refractory bleeding or malignancy. Doppler endoscopic probes aid in risk stratification by detecting residual arterial blood flow, improving the efficacy of endoscopic therapy and reducing rebleeding risks. For small bowel bleeding, endoscopic management with enteroscopy and thermal therapies remains key, though medical therapies are evolving. Lower GIB, which often involves conditions like diverticular disease and angioectasia, requires a comprehensive approach combining endoscopic, radiologic, and surgical interventions. Pharmacologic management focuses on balancing antithrombotic therapy with bleeding risks, with reversal agents playing a crucial role in life-threatening bleeding episodes. This review highlights advances in diagnostic tools and endoscopic therapies that have enhanced management outcomes for GIB across various etiologies.
非静脉曲张性上消化道出血(GIB)仍然是一项重大的临床挑战,30天死亡率高达11%。消化性溃疡是最常见的病因,其次是其他病症,如马洛里-魏斯综合征、迪厄拉富瓦病损和胃部肿瘤。治疗策略包括抑酸治疗、内镜干预以及手术或放射学程序。诸如套扎器、电凝抓钳和内镜超声引导治疗等内镜技术显著改善了治疗效果,降低了再出血率和手术需求。注射疗法、机械止血夹和热凝方式(如电凝、氩离子凝固术)仍然是治疗活动性出血的标准方法。新型止血粉,如TC-325,提供了有前景的非接触式治疗方法,尤其适用于难治性出血或恶性肿瘤病例。多普勒内镜探头通过检测残余动脉血流有助于进行风险分层,提高内镜治疗的疗效并降低再出血风险。对于小肠出血,小肠镜检查和热凝治疗的内镜管理仍然是关键,尽管药物治疗也在不断发展。下消化道出血通常涉及憩室病和血管扩张等病症,需要综合运用内镜、放射学和手术干预措施。药物管理的重点是平衡抗血栓治疗与出血风险,逆转剂在危及生命的出血事件中起着关键作用。本综述强调了诊断工具和内镜治疗方面的进展,这些进展提高了对各种病因引起的上消化道出血的管理效果。